Here's how much Ozempic and similar drugs have soared in popularity since 2018
The findings were reported by MedPageToday on Tuesday, citing a new study published in the Annals of Internal Medicine.
Researchers analyzed data from the Centers for Disease Control and Prevention's (CDC) National Health Interview Survey (NHIS), using an unweighted sample of 90,000 adults. They found that the percentage of U.S. adults without diabetes filling at least one GLP-1 prescription increased from 0.1% in 2018 to 0.4% in 2022 — representing approximately 854,728 adults. By comparison, about 5.1 million adults with type 2 diabetes filled a prescription for the drugs that same year, according to a separate study.
The total number of people taking GLP-1 treatments today could also be much higher. In aMay 2024 survey of 1,479 U.S. adults, about 12% said they'd taken a GLP-1 agonist, and almost one third said they'd heard 'a lot' about these treatments, according to the health policy non-profit KFF.
GLP-1s are a class of drugs that have been used for decades to treat diabetes. They mimic a hormone that helps regulate blood sugar and can also suppress appetite. But a newer generation of these drugs — such as Novo Nordisk's Ozempic and Eli Lilly's (LLY) Mounjaro — has fueled a surge in demand. Unlike older versions, which required daily doses, these newer medications are injected just once a week. Demand skyrocketed even further after the drugs were approved for weight loss. Novo Nordisk's Wegovy received approval to treat obesity in 2021, followed by Eli Lilly's Zepbound in 2023.
By 2022, 65% of GLP-1 users without diabetes were on semaglutide — the active ingredient in Ozempic and Wegovy. Most GLP-1 users without diabetes were female (64%) and white (73%), with an average body mass index (BMI) of 35.7, classifying them as obese.
The blockbuster success of these drugs has transformed Novo Nordisk and Eli Lilly into two of the world's most valuable pharmaceutical companies. Novo Nordisk's total revenue rose 26% in 2024 to $40.5 billion, while Eli Lilly saw a 32% jump, reaching $45 billion.
For the latest news, Facebook, Twitter and Instagram.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
an hour ago
- Time Business News
MK-677 and Its Role in Growth Hormone Studies
When researchers look at ways to study growth hormone and its effects, one compound often comes up in discussion: MK-677. Many people who work in labs or research settings look to purchase MK-677 from trusted sources such as PureRawz. This compound, also called Ibutamoren, has been studied for how it may support growth hormone release in the body. While it is not approved for medical use, it is valued in research because of its unique properties and how it works in controlled studies. MK-677, also known as Ibutamoren, is a compound that acts as a growth hormone secretagogue. That means it helps the body release more growth hormone naturally instead of directly replacing it. Scientists became interested in MK-677 because of its ability to increase both growth hormone (GH) and insulin-like growth factor 1 (IGF-1) in research models. Growth hormone plays an important role in many functions of the body. It supports cell growth, muscle development, recovery, and metabolism. IGF-1 works closely with growth hormone to affect tissue growth and repair. This is why MK-677 has become a point of focus for researchers studying hormones, metabolism, and even aging. MK-677 works by mimicking the hormone ghrelin. Ghrelin is often called the 'hunger hormone,' but it also has a strong role in signaling the release of growth hormone from the pituitary gland. By binding to ghrelin receptors in the brain, MK-677 triggers the same pathways that lead to more growth hormone production. This method is interesting to researchers because it allows the body to keep its natural rhythm of hormone release. Instead of giving growth hormone directly, which can disrupt natural patterns, MK-677 helps maintain a more natural cycle. This makes it a useful compound in controlled growth hormone studies. Over the years, MK-677 has been included in many types of research. Some of the main areas where scientists have shown interest include: Growth hormone is linked to muscle repair and development. In studies, MK-677 has been observed to raise GH and IGF-1 levels, which are both connected to muscle growth. Researchers often look at how MK-677 might play a role in recovery after exercise, injury, or age-related muscle decline. As people age, bone density can decrease, leading to fractures and weakness. Growth hormone and IGF-1 are both important in keeping bones strong. Research has suggested that MK-677 may support bone health by stimulating hormone pathways that affect bone density. Growth hormone release happens most during sleep. Some studies have found that MK-677 may improve sleep quality, especially deep sleep, which is essential for recovery and brain function. Scientists are also curious about whether MK-677 may have an indirect effect on memory and learning through its connection with GH and IGF-1. Growth hormone plays a role in how the body uses fat and builds muscle. In research, MK-677 has been linked with changes in metabolism, including fat storage and energy use. This makes it interesting for studies on obesity, metabolic conditions, and related health concerns. Because growth hormone levels naturally decline with age, researchers have studied MK-677 to see if it could play a role in slowing down age-related changes. While results are still early, the potential link between MK-677, GH, and aging is an area of ongoing interest. When working with compounds like MK-677, quality and purity are very important. That is why researchers often rely on trusted sources such as PureRawz. With so many suppliers online, it can be hard to know which one provides tested and verified products. PureRawz is known for its focus on lab-tested compounds, which makes it a dependable option for researchers who want accurate results in their studies. Buying from a verified source is not just about trust—it also affects the outcome of research. If a compound is not pure, results may not be reliable. For this reason, those who want to purchase MK-677 for study purposes look for vendors like PureRawz that prioritize transparency and testing. It is important to remember that MK-677 is not approved for medical use. Its availability is for research purposes only. Scientists use it in labs to better understand growth hormone and related pathways. Anyone who purchases MK-677 should do so only for controlled research. The role of MK-677 in growth hormone studies continues to expand. While early research has shown promising results in areas like muscle health, sleep, and metabolism, more studies are needed to confirm long-term effects and safety. As interest grows in hormone-related research, MK-677 will likely remain a key compound for study. Whether the focus is aging, recovery, or hormone balance, its ability to stimulate growth hormone release makes it a unique tool for scientists. MK-677, or Ibutamoren, stands out as a research compound because of its effect on growth hormone and IGF-1 levels. By acting like ghrelin, it stimulates natural hormone release in a way that supports multiple areas of study, including muscle health, sleep, metabolism, and aging. For researchers looking to purchase MK-677, choosing a trusted source like PureRawz is essential to ensure quality and reliability. While MK-677 is not for medical use, its role in controlled studies continues to offer valuable insights into how growth hormone works in the body. TIME BUSINESS NEWS
Yahoo
4 hours ago
- Yahoo
Covid-19 Vaccine Guidelines Are Changing. What We Know About Who Can Get a Shot.
It's late August, there's a hurricane coming up the East Coast, schools are starting to open, and no one has any idea who can get an updated Covid-19 shot. It has killed up to 56,000 people in the U.S. since last October, according to the Centers for Disease Control and Prevention, and sickened up to 18 million. Pfizer Moderna and Novavax all plan to launch new versions of their Covid-19 vaccines this fall, updated to target a family of Covid-19 viruses called JN.1.
Boston Globe
5 hours ago
- Boston Globe
GLP-1s, cancer care are driving higher employer health care costs in 2026
Advertisement Companies' strategies for managing the ballooning costs, several experts said, will likely skew toward more aggressive scrutiny of their health insurance carriers and other third-party vendors that help them manage costs, and finding alternatives, if necessary. The higher costs raise the prospect of higher insurance premiums and deductibles for workers, though Ellen Kelsay, CEO of the Business Group on Health, said companies will try to shield employees as much as they can. Kelsay called passing costs on to employees 'a Band-Aid approach' that doesn't fix the long-term cost dynamics. 'Employers are still going to be absorbing 90-plus percent of the health care costs,' Kelsay said on a call with reporters. 'They are still going to do their level best to absorb as much of this cost increase as possible.' Advertisement The 9 percent projected median increase is up from an estimated 8 percent this year and reported increases of 7.5 percent in 2024 and 6.8 percent in 2023. Even if workers don't foot the higher costs directly, the climbing costs of health care can limit the growth of their wages over time. The 9 percent increase is on par with other projections. Last week, the The biggest culprit for higher costs in the Business Group on Health survey is increased use of blockbuster GLP-1 drugs for obesity and diabetes, sold under the brand names Wegovy, Ozempic, Zepbound, and Mounjaro. About 80 percent of respondents to the survey said they've seen an uptick in the use of those drugs, and another 15 percent said they anticipate a future increase. To mitigate GLP-1 expenses, the survey found that the number of employers who cover them for conditions other than diabetes will stagnate. Currently, 99 percent of employers surveyed cover them for diabetes and 73 percent cover them for obesity. Only 6 percent of employers said they had dropped coverage for obesity. Employers that cover GLP-1s for obesity said they'll put more hurdles around their use, such as requiring prescriptions from specific providers and requiring users to participate in weight management programs. Such utilization management tactics are already common. The survey found 90 percent of plans require prior authorization and 54 percent require workers to participate in weight management programs. Advertisement Cancer was the top condition driving employers' health care costs for the fourth year in a row, as diagnoses become more prevalent and the cost of treatment rises. Almost 90 percent of employers said cancer was among the top three conditions costing them the most in 2025, up from 80 percent last year. About half of employers plan to steer their workers toward specific cancer centers that offer quality services at lower costs, known as centers of excellence, in 2026, and another 23 percent will consider doing so by 2028. Other conditions were less likely to show up in employers' top three lists for costs. Diabetes dropped from 28 percent in 2024 to 21 percent in 2025. Musculoskeletal conditions dropped from 74 percent to 71 percent and cardiovascular conditions dropped from 40 percent to 35 percent. Almost three-quarters of employers said their workers are seeking out mental health and substance use disorder treatment at higher rates, and another 17 percent anticipate future increases. Another area that's driving higher spending is more coverage for women's health needs. Next year, 58 percent of employers said they plan to expand preventive care for women, an increase of 22 percentage points in two years. Almost 60 percent of employers said they'll provide menopause support services next year, up from 28 percent in 2024. Other services are also on the rise. In 2026, 36 percent of employers will cover doula services, 55 percent will cover services to treat postpartum depression, and 43 percent will cover initiatives to support high-risk pregnancies in under-resourced populations. Robert Andrews, CEO of the Health Transformation Alliance, a coalition of about 80 self-insured employers that cover 5 million people, said that while he hasn't done a formal survey, he's hearing that costs are rising 7 percent to 9 percent at the median. That said, some of his group's members have kept costs flat. The latter are companies that are aggressive about auditing claims and not paying erroneous, fraudulent, or otherwise inflated claims. Advertisement Another piece of advice Andrews gives members is to carefully review their agreements with carriers. 'Watch your carrier very closely, audit the carrier, make sure you're getting the deal that you bargained for,' he said. Andrews also recommends companies put a cap on out-of-network charges for employees who have to get care at out-of-network hospitals. Not only that, make sure the insurer is actually enforcing the cap, because often it's not, he said. One of the Business Group on Health's members is Delta Airlines, where the cost increases are consistently in the low single digits, said Henry Ting, the company's chief health and wellness officer. 'That's not just an accident or by chance,' said Ting, a cardiologist who worked at Mayo Clinic for over two decades. 'We do take a lot of actions to make sure we're delivering the best value.' Delta's approach to keeping health insurance costs down Delta has collected over 10 billion de-identified records from its 100,000 employees and their dependents and used it to see where the high costs are. One revelation was that a significant percentage of cancers among employees were diagnosed because of symptoms and not through screening tests. Those people also tended to have more advanced disease. Delta now has a 'Living Well with Dr. Henry' series for employees in which Ting educates people on screenings. Advertisement 'Then we make it easy for them to schedule those appointments without a lot of friction,' Ting said. 'I'd like to have 99 percent of our cancers diagnosed on a routine screening test rather than feeling a lump or pain or bleeding.' The Commonwealth Fund last year convened a One of the task force members is Paul Fronstin, who serves as director of health benefits research at the Employee Benefit Research Institute. When it comes to strategies for cutting down on costs, Fronstin said he thinks employers will scrutinize vendors, make changes to plan designs and networks, and use so-called point solutions, which are vendors that help patients manage specific conditions, like type 2 diabetes or mental health conditions. But with unemployment still at record lows, Fronstin thinks retention will be front of mind for employers, making them hesitant to shift costs onto employees. 'We've seen in the past that employers haven't increased premiums,' he said, 'or to the degree premiums have gone up for employees, they've gone up in proportion to what the employer pays.'
